Amanda Leach

Summary

Affiliation: GlaxoSmithKline Biologicals
Country: Belgium

Publications

  1. pmc Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region
    Salim Abdulla
    Bagamoyo Research and Training Centre of Ifakara Health Institute, Pwani, Tanzania
    Malar J 12:11. 2013
  2. pmc Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa
    Amanda Leach
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Malar J 10:224. 2011
  3. doi request reprint Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials
    Johan Vekemans
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Hum Vaccin 7:1309-16. 2011
  4. ncbi request reprint From the circumsporozoite protein to the RTS, S/AS candidate vaccine
    Joe Cohen
    GlaxoSmithKline Biologicals, Belgium
    Hum Vaccin 6:90-6. 2010
  5. pmc Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children
    Marc Lievens
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Malar J 10:222. 2011
  6. pmc Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care
    Johan Vekemans
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Malar J 10:221. 2011
  7. doi request reprint Development of the RTS,S/AS malaria candidate vaccine
    Johan Vekemans
    GlaxoSmithKline Biologicals, 89 Rue de l Institut, 1330 Rixensart, Belgium
    Vaccine 27:G67-71. 2009

Detail Information

Publications7

  1. pmc Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region
    Salim Abdulla
    Bagamoyo Research and Training Centre of Ifakara Health Institute, Pwani, Tanzania
    Malar J 12:11. 2013
    ..This paper describes results following 20 months of follow up...
  2. pmc Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa
    Amanda Leach
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Malar J 10:224. 2011
    ..This paper details the design of the phase III multicentre efficacy trial of the RTS,S/AS01 malaria vaccine candidate, which is pivotal for licensure and policy decision-making...
  3. doi request reprint Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials
    Johan Vekemans
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Hum Vaccin 7:1309-16. 2011
    ..Significant decreased relative risks of death, any SAE, any SAE excluding malaria and pneumonia were observed. The results suggest a favourable risk-benefit balance which is to be confirmed in the ongoing Phase III trials...
  4. ncbi request reprint From the circumsporozoite protein to the RTS, S/AS candidate vaccine
    Joe Cohen
    GlaxoSmithKline Biologicals, Belgium
    Hum Vaccin 6:90-6. 2010
    ....
  5. pmc Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children
    Marc Lievens
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Malar J 10:222. 2011
    ..There has been much debate about the appropriate statistical methodology for the evaluation of malaria field studies and the challenges in interpreting data arising from these trials...
  6. pmc Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care
    Johan Vekemans
    GlaxoSmithKline Biologicals, Wavre, Belgium
    Malar J 10:221. 2011
    ..This paper describes the case definitions of severe malaria used in this study and the programme for standardized assessment of severe malaria according to the case definition...
  7. doi request reprint Development of the RTS,S/AS malaria candidate vaccine
    Johan Vekemans
    GlaxoSmithKline Biologicals, 89 Rue de l Institut, 1330 Rixensart, Belgium
    Vaccine 27:G67-71. 2009
    ....